Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human APOE*2

Journal of Clinical Investigation

Volumn 102, Issue 1, 1998, Pages 130-135

  Sullivan, Patrick M ^a   Mezdour, Hafid ^a   Quarfordt, Steven H ^b   Maeda, Nobuyo ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein E; Clofibrate; Gene targeting; Planar xanthoma; VLDL clearance

Indexed keywords

APOLIPOPROTEIN E; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; GENE TARGETING; HISTOPATHOLOGY; HYPERLIPOPROTEINEMIA; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; XANTHOMA;

EID: 0032128001     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI2673     Document Type: Article

References (28)

1. Maley, R.W., and S.C. Rall, Jr. 1995. Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In The Metabolic and Molecular Basis of Inherited Diseases. A.L. Beaudet, W.S. Sly, and D. Valle, editors. MacGraw-Hill, New York. 1953-1980.
2. Weisgraber K.H., T.L. Innerarity, and R.W. Mahley. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-areinine interchange at a single site. J. Biol. Chem. 257:2518-2521.
3. Utermann, G., M. Hees, and A. Steinmetz. 1977. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man. Nature. 269: 604-607.
4. Fazio, S., Y.-L. Lee, Z.-S. Ji, and S.C. Rall, Jr. 1993. Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E. J. Clin. Invest. 92:1497-1503.
5. van den Maagdenberg, A.M.J.M., M.H. Hofker, P.J.A. Krimpenfort, I. de Bruijn, B. van Vlijmen, H. van der Boom, L.M. Havekes, and R.R. Frants. 1993. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol. Chem. 268:10540-10545.
6. van Vlijmen, B.J.M., K.W. van Dijk, H.B. van't Hof, P.J.J. van Gorp, A. van der Zee, H. van der Boom, M.L. Breuer, M.H. Hofker, and L.M. Havekes. 1996. In the absence of endogenous mouse apolipoprotein E. apolipoprotein E*2 (Arg158Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice. J. Biol. Chem. 271:30595-30602.
7. Huang, Y., S.W. Schwendner, S.C. Rall, Jr., and R.W. Mahley. 1996. Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2. J. Biol. Chem. 271:29146-29151.
8. Huang, Y., S.W. Schwendner, S.C. Rall, DA. Sanan, and R.W. Mahley. 1997. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. J. Biol. Chem. 272:22685-22694.
9. Huang, Y., S.C. Rall, Jr., and R.W. Mahley. 1997. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. Arterioscler. Thromb. Vasc. Biol. 17:2817-2824.
10. Sullivan, P.M., H. Mezdour, Y. Aratani, C. Knouff, J. Najib, R.L. Reddick, S.H. Quarfordt, and N. Maeda. 1997. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272:17972-17980.
11. Hackler, R., J.R. Schafer, S. Motzny, S. Brand, T.O. Kleine, H. Kaffarnik, and A. Steinmetz. 1994. Rapid determination of apolipoprotein E phenotypes from whole plasma by automated isoelectric focusing using PhastSystem and immunofixation. J. Lipid Res. 35:153-158.
12. Quarfordt, S.H., B. Oswald, B. Landis, H.S. Xu, S.H. Zhang, and N. Maeda. 1995. In vivo cholesterol kinetics in apolipoprotein E-deficient and control mice. J. Lipid Res. 36:1227-1235.
13. Zhang, S.H., R.L. Reddick, J.A. Piedrahita, and N. Maeda. 1992. Spon, taneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468-471.
14. Fredrickson, D.S., R.I. Levy, and R.S. Lees. 1967. Fat transport in lipoproteins-an integrated approach to mechanisms and disorders. N. Engl. J. Med. 276:34-44.
15. Hazzard, W.R., and E.L. Bierman. 1975. Broad-β disease versus endogenous hypertriglyceridemia: levels and lipid composition of chylomicrons and very low density lipoproteins during fat-free feeding and alimentary lipemia. Metabolism. 24:817-828.
16. Chappell, D.A. 1988. Pre-beta-very low density lipoproteins as precursors of beta-very low density lipoproteins. A model for the pathogenesis of familial dysbetalipoproteinemia (type III hyperlipoproteinemia). J. Clin. Invest. 82:628-639.
17. Schaeffer, E.J., and R.I. Levy. 1985. Pathogenesis and management of lipoprotein disorders. N. Engl. J. Med. 312:1300-1310.
18. Brewer, H.B. Jr., L.A. Zech, R.E. Gregg, D. Schwartz, and E.J. Schaefer. 1983. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann. Intern. Med. 98:623-640.
19. Hoogwerf, B.J., J.P. Bantle, K. Kuba, I.D. Frantz, Jr., and D.B. Hunninghake. 1984. Treatment of type III hyperlipoproteinemia with four different treatment regimens. Atherosclerosis. 51:251-259.
20. Polano, M.K. 1974. Xanthomatosis and hyperlipoproteinemia. A review. Dermatologica. 149:1-9.
21. Parker, F. 1985. Xanthomas and hyperlipidemias. J. Am. Acad. Dermatol. 13:1-30.
22. Nishina, P.M., J. Verstuyft, and B. Paigen. 1990. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J. Lipid Res. 31:859-869.
23. Greeve, J., I. Altkemper, J.H. Dieterich, H. Greten, and E. Windler. 1993. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J. Lipid Res. 34:1367-1383.
24. Higuchi, K., K. Kitagawa, K. Kogishi, and T. Takeda. 1992. Developmental and age-related changes in apolipoprotein B mRNA editing in mice. J. Lipid Res. 33:1753-1764.
25. Plump, A.S., D.J. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J.G. Verstuyft, E.M. Rubin, and J.L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
26. Zhang, S.H., R.L. Reddick, B. Burkey, and N. Maeda. 1994. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J. Clin. Invest. 94:937-945.
27. Goldstein, J.L., Y.K. Ho, S.K. Basu, and M.S. Brown. 1979. Binding sites on macrophages that mediate uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA. 76:333-337.
28. Henricksen, T., E.M. Mahoney, and D. Steinberg. 1981. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc. Natl. Acad. Sci. USA. 78:6499-6503.